NASDAQ
IKNA

Ikena Oncology Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Ikena Oncology Inc Stock Price

Vitals

Today's Low:
$4.16
Today's High:
$4.56
Open Price:
$4.34
52W Low:
$1.94
52W High:
$7.64
Prev. Close:
$4.33
Volume:
72161

Company Statistics

Market Cap.:
$203.89 million
Book Value:
3.705
Revenue TTM:
$19.17 million
Operating Margin TTM:
-349.52%
Gross Profit TTM:
$-48703000
Profit Margin:
0%
Return on Assets TTM:
-21.87%
Return on Equity TTM:
-37.92%

Company Profile

Ikena Oncology Inc had its IPO on 2021-03-26 under the ticker symbol IKNA.

The company operates in the Healthcare sector and Biotechnology industry. Ikena Oncology Inc has a staff strength of 59 employees.

Stock update

Shares of Ikena Oncology Inc opened at $4.34 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.16 - $4.56, and closed at $4.24.

This is a -2.08% slip from the previous day's closing price.

A total volume of 72,161 shares were traded at the close of the day’s session.

In the last one week, shares of Ikena Oncology Inc have slipped by -12.03%.

Ikena Oncology Inc's Key Ratios

Ikena Oncology Inc has a market cap of $203.89 million, indicating a price to book ratio of 0.6599 and a price to sales ratio of 3.1264.

In the last 12-months Ikena Oncology Inc’s revenue was $19.17 million with a gross profit of $-48703000 and an EBITDA of $-66100000. The EBITDA ratio measures Ikena Oncology Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ikena Oncology Inc’s operating margin was -349.52% while its return on assets stood at -21.87% with a return of equity of -37.92%.

In Q2, Ikena Oncology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 424.6%.

Ikena Oncology Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ikena Oncology Inc’s profitability.

Ikena Oncology Inc stock is trading at a EV to sales ratio of 0.2082 and a EV to EBITDA ratio of 0.9683. Its price to sales ratio in the trailing 12-months stood at 3.1264.

Ikena Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$171.76 million
Total Liabilities
$12.01 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Ikena Oncology Inc ended 2024 with $171.76 million in total assets and $0 in total liabilities. Its intangible assets were valued at $171.76 million while shareholder equity stood at $156.70 million.

Ikena Oncology Inc ended 2024 with $0 in deferred long-term liabilities, $12.01 million in other current liabilities, 42000.00 in common stock, $-245553000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $70.87 million and cash and short-term investments were $157.31 million. The company’s total short-term debt was $1,937,000 while long-term debt stood at $0.

Ikena Oncology Inc’s total current assets stands at $160.65 million while long-term investments were $0 and short-term investments were $86.44 million. Its net receivables were $0 compared to accounts payable of $1.77 million and inventory worth $0.

In 2024, Ikena Oncology Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Ikena Oncology Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4.24
52-Week High
$7.64
52-Week Low
$1.94
Analyst Target Price
$17.33

Ikena Oncology Inc stock is currently trading at $4.24 per share. It touched a 52-week high of $7.64 and a 52-week low of $7.64. Analysts tracking the stock have a 12-month average target price of $17.33.

Its 50-day moving average was $5.19 and 200-day moving average was $4.67 The short ratio stood at 10.46 indicating a short percent outstanding of 0%.

Around 34.2% of the company’s stock are held by insiders while 7375.3% are held by institutions.

Frequently Asked Questions About Ikena Oncology Inc

The stock symbol (also called stock or share ticker) of Ikena Oncology Inc is IKNA

The IPO of Ikena Oncology Inc took place on 2021-03-26

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$52.5
-0.51
-0.96%
$0.37
0.02
+6.46%
CONX Corp (CONXU)
$10.35
0
0%
$0.74
-0.01
-1.33%
$318.8
-10
-3.04%
$38.14
1.52
+4.15%
$0.05
-0
-5.25%
$3.3
-0.41
-11.05%
$1832.8
-166.05
-8.31%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Address

645 Summer Street, Boston, MA, United States, 02210